UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000004420
Receipt No. R000005278
Scientific Title Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT)
Date of disclosure of the study information 2010/10/20
Last modified on 2017/10/05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT)
Acronym JSCT-NHL10
Scientific Title Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT)
Scientific Title:Acronym JSCT-NHL10
Region
Japan

Condition
Condition Diffuse large B-cell lymphoma
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The purpose of this study is to determine whether a PET scan after 2 cycles of R-CHOP can help guided therapy for patients with high-intermediate or high risk DLBCL.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Progression-free survival at 2 years of patients with a persistently positive PET scan after 2 cycles of R-CHOP
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine Device,equipment
Interventions/Control_1 Patients who have a positive PET scan after 2 cycles of R-CHOP will receive total 6 cycles of standard R-CHOP followed by HDC/ASCT.
Interventions/Control_2 Patients who have a negative PET scan after 2 cycles of R-CHOP will complete treatment with total 8 cycles of standard R-CHOP.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit
65 years-old >=
Gender Male and Female
Key inclusion criteria 1.Newly diagnosed NHL by tissue biopsy; DLBCL, listed under mature B-cell neoplasms according to the WHO classification (diffuse large B-cell lymphoma/NOS, primary mediastinal large B-cell lymphoma, excluding intravascular large B-cell lymphoma).
2.Histologically proven CD20 positive DLBCL.
3.Patients with measurable disease by CT scan.
4.Age: 15-65.
5.Ann Arbor stage: 2-4.
6.Performance status (ECOG): 0-3.
7.Age-adjusted International Prognostic Index (aaIPI): High or High-intermediate.
8.Adequate hematological, hepatic, renal, cardiac, or pulmonary function (Neutrophil count >=1000/mm3, Platelet count >=7.5X104/mm3, AST<=3 X upper limit of normal, ALT<=3 X upper limit of normal, T. Bil<=2.0mg/dL, Cr<=2.0mg/dL, EF>=50%, PaO2>=60 mmHg or SaO2>=90%).
9.Patients without severe complications.
10.The patient must sign the consent form prior to registration. If the patient is under age, both the guardian and the patient must sign the consent form.
Key exclusion criteria 1.Patients with a history of prior or concurrent malignancies.
2.Patients who are on any medication for diabetes.
3.Patients who have severe complications such as active systematic infection, heart failure, respiratory failure, pulmonary disease, hepatic failure, liver cirrhosis, acute or chronic hepatitis, renal failure, active tuberculosis.
4.Patients with a history of angina or cardiac infarction. Patients with cardiomyopathy. Patients taking anti-arrhythmic drugs.
5.Patients with a history of drug anaphylaxis.
6.Patients with severe mental illness.
7.Patients with a history of lymphoma, leukemia, or MDS.
8.Patients with a history of chemotherapy, cytokine therapy, or antibody therapy for present DLBCL.
9.Patients with primary central nervous system lymphoma or with central nervous system involvement of DLBCL
10.Pregnancy or lactation.
11.Known hepatitis B or C virus infection
12.Known HIV or HTLV-1 infection
13.Patients with any medical condition that in the opinion of the investigator would compromise treatment delivery.
Target sample size 68

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Koji Kato
Organization Kyushu Univ. Hospital
Division name Department of Hematology
Zip code
Address Fukuoka, Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization JSCT
Division name NHL10 datacenter
Zip code
Address
TEL
Homepage URL
Email jsct-office@umin.ac.jp

Sponsor
Institute Japan Study Group for Cell Therapy and Transplantation
Institute
Department

Funding Source
Organization Resarch Foundation for Community Medicine
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2010 Year 10 Month 20 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2010 Year 10 Month 20 Day
Date of IRB
Anticipated trial start date
2010 Year 11 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2010 Year 10 Month 20 Day
Last modified on
2017 Year 10 Month 05 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005278

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.